Sarcoidosis associated with pembrolizumab alone or in combination with chemotherapy agents: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)

被引：0
|
作者：
Pawar, Mansi [1 ]
Lukose, Lipin [1 ]
Viswam, Subeesh K. [2 ]
Salim, Mohammed K. T. [3 ]
机构：
[1] Manipal Coll Pharmaceut, Manipal, India
[2] Cactus Communicat Private Ltd, Cactus Life Sci, Mumbai, Maharashtra, India
[3] Manipal Acad Higher Educ, Dept Pharm Practice, Manipal Coll Pharmaceut Sci, Manipal, India
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：639 / 639
页数：1
相关论文
共 50 条
  • [41] Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022
    Du, Yikuan
    Zhu, Jinfeng
    Guo, Zhuoming
    Wang, Zhenjie
    Wang, Yuni
    Hu, Mianda
    Zhang, Lingzhi
    Yang, Yurong
    Wang, Jinjin
    Huang, Yixing
    Huang, Peiying
    Chen, Mianhai
    Chen, Bo
    Yang, Chun
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (02) : 189 - 201
  • [42] Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study
    Bangbei Wan
    Zhi Zhou
    Ning Ma
    Weiying Lu
    European Journal of Medical Research, 30 (1)
  • [43] Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system
    Chufeng Ding
    Lin Ma
    Yankun Liang
    Zhenpo Zhang
    Qimin Wu
    Jun Lyu
    Ling Su
    Scientific Reports, 15 (1)
  • [44] Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
    Pan, Xianglin
    Xiao, Xiangtian
    Ding, Yiling
    Shu, Yamin
    Zhang, Wenting
    Huang, Liu
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [45] A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab
    Chen, Zepeng
    Li, Ming
    Li, Shuzhen
    Li, Yuxi
    Wu, Junyan
    Qiu, Kaifeng
    Yu, Xiaoxia
    Huang, Lin
    Chen, Guanghui
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (04) : 339 - 342
  • [46] A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)
    Shi, X.
    Cheng, Q.
    Zhao, Y. -z.
    Zou, S. -p.
    Sun, M. -h.
    OSTEOPOROSIS INTERNATIONAL, 2023, 34 (12) : 2047 - 2058
  • [47] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
    Yin, Yanchao
    Shu, Yamin
    Zhu, Junru
    Li, Feie
    Li, Juan
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [48] A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
    Menglin Guo
    Yamin Shu
    Guosong Chen
    Juan Li
    Feie Li
    Scientific Reports, 12
  • [49] A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
    Zou, Fan
    Zhu, Chengyu
    Lou, Siyu
    Cui, Zhiwei
    Wang, Dan
    Ou, Yingyong
    Wang, Li
    Chen, Junyou
    Lan, Yuanbo
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [50] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
    Yanchao Yin
    Yamin Shu
    Junru Zhu
    Feie Li
    Juan Li
    Scientific Reports, 12
12345